Axillary Access for Microaxial Ventricular Support Device Placement

There is little evidence in support of the axillary access for counterpulsation balloon insertion, but this evidence is null when it comes to microaxial ventricular support device placement (the Impella device family). 

Acceso percutáneo axilar para dispositivos de asistencia ventricular

Clinical indication of short-term mechanical circulatory support devices has been on the rise. Many patients present suboptimal iliofemoral access or early mobilization is required. 

Axillary artery access is an option for these patients, and this is the rationale behind the ARMS Registry (Axillary Access Registry to Monitor Safety) which prospectively included patients to analyze the feasibility and safety of this procedure. 

A total 102 patients from 10 centers were included. Successful device implantation was 98% and support lasted mean 2 days (range 0-35 days). Postprocedural access site hematoma or bleeding was noted in 9 patients. 

Major complications included 10 bleedings and one stroke. Minor complications included 3 patients presenting, after several days, C8 tingling consistent with brachial plexus related symptoms. 


Read also: Intravascular Imaging: A Universal Approach for Angioplasty Optimization.


Device explantation was done with closure devices alone in 61% of cases, stent grafts in 17%, balloon tamponade facilitated closure in 15%, and planned surgical explant in 5%. 

Support duration was independently associated with vascular complications and increased complications by 1.1% per day.

Conclusion

Percutaneous axillary access of microaxial support pumps (Impella family) appears feasible with acceptable rates of bleeding, despite the early experience.

Original Title: Percutaneous Axillary Access for Placement of Microaxial Ventricular Support Devices. The Axillary Access Registry to Monitor Safety (ARMS).

Reference: James M. McCabe et al. Circ Cardiovasc Interv. 2021;14:e009657. DOI: 10.1161/CIRCINTERVENTIONS.120.009657.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....